United States Federal Circuit
Bayer Healthcare Pharmaceuticals, Inc. v. Watson Pharmaceuticals, Inc., 2012-1397
In consolidated patent infringement actions by generic pharmaceutical company defendants relating to combined oral contraceptive (COC) products, the District Court's entry of summary judgment on the grounds that claims 13 and 15 of Bayer's U.S. Patent RE37,564 are not invalid for obviousness, is reversed where none of the evidence presented overcomes the plain disclosures and express motivation to combine those disclosures in the prior art.
Appellate Information
- Decided 04/16/2013
- Published 04/16/2013
Judges
- Lourie
Court
- United States Federal Circuit